Product Description
Avoralstat is a small molecule inhibitor of plasma kallikrein. Avoralstat (formerly BCX4161) is a potent, small molecule inhibitor of kallikrein that was discovered at BioCryst Pharmaceuticals, Inc.12 Effective inhibition of kallikrein with an orally bioavailable small molecule such as avoralstat may have significant benefits for patients with C1‐INH‐HAE by reducing the frequency of angioedema attacks. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175137/)
Mechanisms of Action: KLK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioCryst
Company Location: DURHAM NC 27703
Company CEO: Jon P. Stonehouse
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Angioedemas, Hereditary
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| OPuS 4 - Long term safety study of avoralstat | P3 |
Terminated |
Angioedemas, Hereditary |
2016-02-26 |
|
| OPuS-4 | P3 |
Terminated |
Angioedemas, Hereditary |
2016-02-01 |
|
| OPuS 2 | P3 |
Completed |
Angioedemas, Hereditary |
2016-01-08 |
|
| OPuS-2 | P3 |
Completed |
Angioedemas, Hereditary |
2016-01-01 |